Inventor · disambiguated record
Heidi Lane
Also filed as: LANE HEIDI · LANE HEIDI A · LANE HEIDI ALEXANDRA
16 granted patents·25 pending applications·29 citations·filing 2002–2023
90Inventor score
Files withLANE HEIDI9BASILEA PHARM INT AG8LANE HEIDI ALEXANDRA5NOVARTIS AG5BASILEA PHARMACEUTICA AG4
Top patents by PatentIndex Score
41 records- 0183US8778962B2Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2012·Granted Jul 15, 2014·4 cites·6 claims
- 0282US8410131B2Cancer treatmentLANE HEIDI·Filed 2002·Granted Apr 2, 2013·11 cites·9 claims
- 0381US9970938B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2016·Granted May 15, 2018·2 cites·60 claims
- 0477US10067120B2Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2016·Granted Sep 4, 2018·2 cites·59 claims
- 0577US10006078B2Use of phospho-Akt as a biomarker of drug responseLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 26, 2018·2 cites·81 claims
- 0674US9995754B2Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 12, 2018·2 cites·28 claims
- 0773US9366682B2Use of stathmin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 14, 2016·3 cites·97 claims
- 0873US7749698B2p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agentNOVARTIS AG·Filed 2005·Granted Jul 6, 2010·1 cites·5 claims
- 0972US9476889B2Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Oct 25, 2016·2 cites·78 claims
- 1064US8877771B2Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2013·Granted Nov 4, 2014·0 cites·22 claims
- 1164US2009105285A1Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitorNOVARTIS AG·Filed 2007·Application pending·0 cites
- 1263US2014105895A1Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2013·Application pending·0 cites
- 1361US10724072B2Use of phospho-Akt as a biomarker of drug responseBASILEA PHARMACEUTICA AG·Filed 2018·Granted Jul 28, 2020·0 cites·65 claims
- 1461US10656162B2Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2018·Granted May 19, 2020·0 cites·48 claims
- 1561US8436010B2Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2012·Granted May 7, 2013·0 cites·11 claims
- 1661US2016303092A1Treatment of solid tumors with rapamycin derivativesNOVARTIS PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 1761US2013244951A1Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2013·Application pending·0 cites
- 1861US2013253000A1Treatment of solid tumors with rapamycin derivativesLANE HEIDI·Filed 2013·Application pending·0 cites
- 1957US2009099103A1Combinations of therapeutic agents for treating cancerNOVARTIS AG·Filed 2007·Application pending·0 cites
- 2055US2025057844A1Methods of treating neoplastic diseasesSILLAJEN INC·Filed 2022·Application pending·0 cites
- 2154US2009098137A1Combinations of therapeutic agents for treating cancerNOVARTIS AG·Filed 2007·Application pending·0 cites
- 2251US2025049801A1Pharmaceutical combinations for use in the treatment of neoplastic diseasesSILLAJEN INC·Filed 2022·Application pending·0 cites
- 2351US2022370418A1Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2020·Application pending·0 cites
- 2449US2012129881A1Combinations of therapeutic agents for treating cancerBURKE GREGORY·Filed 2011·Application pending·0 cites
- 2549US2025161310A1Pharmaceutical combinations for use in the treatment of neoplastic diseasesSILLAJEN INC·Filed 2023·Application pending·0 cites
- 2649US2008214596A1Biomarkers for sensitivity of proliferative diseases to mtor inhibitorsBOULAY ANNE·Filed 2008·Application pending·0 cites
- 2747US2009012105A1Combination of Mtor Inhibitor and Antipolate CompoundNOVARTIS AG·Filed 2008·Application pending·0 cites
- 2845US2020031811A1Substituted mono- and polyazanaphthalene derivatives and their useBASILEA PHARM INT AG·Filed 2019·Application pending·0 cites
- 2945US2008085902A1Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic AgentBOLD GUIDO·Filed 2004·Application pending·0 cites
- 3045US2011301184A1Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitorLANE HEIDI·Filed 2011·Application pending·0 cites
- 3144US10222377B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Mar 5, 2019·0 cites·61 claims
- 3244US2007167478A1Biomarkers for sensitivity of proliferative diseases to mtor inhibitorsBOULAY ANNE·Filed 2004·Application pending·0 cites
- 3343US2010305150A1Tuberous sclerosis treatmentBERG WILLIAM·Filed 2007·Application pending·0 cites
- 3443US2008200486A1Combination Of Organic CompoundsLANE HEIDI·Filed 2006·Application pending·0 cites
- 3542US2022402900A11,2,4-oxadiazol-5-one derivatives for the treatment of cancerBASILEA PHARM INT AG·Filed 2020·Application pending·0 cites
- 3638US2022031670A1Pharmaceutical combinations for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2019·Application pending·0 cites
- 3737US11419856B2Pharmaceutical combinations for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2018·Granted Aug 23, 2022·0 cites·32 claims
- 3837US10487075B2Substituted mono- and polyazanaphthalene derivatives and their useBASILEA PHARM INT AG·Filed 2016·Granted Nov 26, 2019·0 cites·41 claims
- 3936US2011195072A1Non-neuroendocrine cancer therapyBOULAY ANNE·Filed 2007·Application pending·0 cites
- 4033US2018306790A1Use of eb1 as a biomarker of drug responseBASILEA PHARM INT AG·Filed 2016·Application pending·0 cites
- 4128US2019142810A1Mitochondrial inhibitors for the treatment of proliferation disordersBASILEA PHARM INT AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Heidi Lane files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →